JAK2 and myeloproliferative neoplasm: The IGF1R/IRS inhibitor NT157 was able to decrease JAK2/STAT signaling, proliferation, and viability in JAK2 V617F-positive cell lines [97], while PI3K pathway inhibitors synergized with JAK2 inhibitors in MPN [96].